Methods are described for the covalent attachment of succinoyl-Ala-Ala-Pro-ValCH2Cl, an active sitedirected inhibitor of human leukocyte elastase (EC 3.4.21.11), to microspheres of human albumin. (EC 3.4.21.11), an enzyme that has been implicated in lung tissue injury resulting in the development of emphysema (6, 7). Although these inhibitors would appear to offer promise for the treatment of emphysema, their therapeutic effectiveness would be considerably enhanced if they could be targeted directly to the lungs. As a step in this direction we report here the manner in which the succinoyl peptide chloromethyl ketone (SPCK) succinoyl (Suc)-AlaAla-Pro-ValCH2Cl, which has been shown to be one of the more potent inhibitors of human leukocyte elastase (5), may be covalently attached to HAM with the retention of significant inhibitory activity towards this enzyme. Also reported here are the results of preliminary experiments in vio that show that the carrier-borne inhibitor is in fact targeted primarily to the lungs, where about half of the injected dose has a half-life of approximately 17 days. (8) and is currently available in kit form as a carrier of radioactive tracers for diagnostic lung scanning (2-4), circulatory studies (9), and cardiac output (10). SPCK was synthesized as described (5). Ethylenediamine, 5,5'-dithiobis-(2-nitrobenzoic acid), and hexanediamine were purchased from Aldrich; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-acetylglycine from Sigma; ethyleneimine from Pierce; N-acetyl-DL-homocysteine thiolactone from Schwarz/Mann; and iodo[1-'4C]acetic acid and Na125I (carrier-free) from New England Nuclear. All other chemicals were reagent grade available from commercial sources. All aqueous reagents which were used during the course of the derivatization of HAM contained 0.025% Pluronic F-68 (BASF, Wyandotte, MI) in order to prevent the adherence of microspheres to the sides of reaction vessels and to facilitate uniform suspension.
which rats were injected intravenously with radiolabeled microspheres to which the inhibitor had been attached showed a rapid and exclusive uptake by the lungs. About 40-50% of the injected microspheres subsequently remained in the lungs with a alf-life of approximately 17 days. These derivatized microspheres thus appear to offer promise as a therapeutic agent for emphysema.
One approach to the delivery of therapeutic agents in vivo involves their attachment to a suitable carrier that can be targeted to the desired site of action (1) . Human albumin microspheres (HAM) offer considerable potential in this regard because they are nontoxic, nonantigenic, and biodegradable, and, because of their unique size, show a high selectivity for the lung tissue, where they become trapped in the pulmonary capillary bed after intravenous injection (2) (3) (4) . HAM are prepared from a solution of human serum albumin heated in hot vegetable oil. The microspheres thus produced are rendered free of oil by washing with an organic solvent and then carefully sieved to give a narrow range of particle sizes. Although the functional groups of HAM should permit the covalent attachment of a wide variety of ligands, this possibility does not appear to have received much attention.
Powers et al. (5) have recently reported the synthesis of peptide chloromethyl ketones that are specific inhibitors of human leukocyte elastase (EC 3.4.21.11), an enzyme that has been implicated in lung tissue injury resulting in the development of emphysema (6, 7) . Although these inhibitors would appear to offer promise for the treatment of emphysema, their therapeutic effectiveness would be considerably enhanced if they could be targeted directly to the lungs. As a step in this direction we report here the manner in which the succinoyl peptide chloromethyl ketone (SPCK) succinoyl (Suc)-AlaAla-Pro-ValCH2Cl, which has been shown to be one of the more potent inhibitors of human leukocyte elastase (5) (2) (3) (4) , circulatory studies (9), and cardiac output (10) . SPCK was synthesized as described (5) . Ethylenediamine, 5,5'-dithiobis-(2-nitrobenzoic acid), and hexanediamine were purchased from Aldrich; 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-acetylglycine from Sigma; ethyleneimine from Pierce; N-acetyl-DL-homocysteine thiolactone from Schwarz/Mann; and iodo[1-'4C]acetic acid and Na125I (carrier-free) from New England Nuclear. All other chemicals were reagent grade available from commercial sources. All aqueous reagents which were used during the course of the derivatization of HAM contained 0.025% Pluronic F-68 (BASF, Wyandotte, MI) in order to prevent the adherence of microspheres to the sides of reaction vessels and to facilitate uniform suspension.
The sequence of reactions involved in the covalent attachment of SPCK to HAM with extended side chains is described in detail in the legend accompanying Fig. 1 . Briefly, the exposed carboxyl groups of HAM were first aminoethylated (step 1), and the amino groups so introduced (I), plus any amino groups already exposed on the surface of HAM, were thiolated with N-acetyl-DL-homocysteine thiolactone (step 2). The thiolated derivative (II) was again aminoethylated with ethyleneimine (step 3) to give the amino derivative (III), or with iodoacetate (step 4) to give the carboxyl derivative (IV). The side chain of IV could be further elongated by condensation with hexanediamine (step 5), yielding V. By virtue of the succinoyl group at the NH2 terminus of the peptide, the latter could be condensed with the amino groups of I, III, and V (step 6), thus yielding HAM-inhibitor derivatives denoted as Ii, IIIi, and Vi, respectively.
Assay for Enzyme Activity. Human leukocyte elastase was prepared from purulent sputum as described (12) and was determined to be 95% active by titration with the p-nitrophenyl carbazate derivative of acetyltrialanine (13) . Elastase activity was determined with succinoyltrialanyl-p-nitroanilide (14) purchased from Calbiochem.
In Vivo Studies. Derivative Sequence of reactions involved in the synthesis of microspheres to which SPCK has been attached via spacer groups of various lengths.
Step 1: 1 ml of ethylenediamine was added to 50 mg of HAM in 2 ml of H20, and the pH was adjusted to 4.75, followed by the addition of 60 mg of EDC. The suspension was stirred for 2 hr at room temperature while the pH was maintained at 4.75 to 5.0. Aminoethylated HAM (I) was sequentially washed with 1 liter of 0.5 M NaCl, 2 liters of H20, and 500 ml of acetone.
Step 2: I was suspended in 10 ml of 1 M NaHCO3, pH 9.7, to which was then added 0.5 g of N-acetyl-DL-homocysteine thiolactone. The suspension was allowed to react for 24 hr at 5°C with continuous stirring, and thiolated-HAM (II) was washed as before.
Step 3: II was suspended in 10 ml of 0.67 iodine by the procedure of Davidson (15) and, after the removal of free 125I by filtration in a Buchner funnel, was converted to IIIi as described in the legend to Fig. 1 . This preparation con-
RESULTS

Synthesis and inhibitory activity of inhibitor-bound microspheres
In order to assess the efficiency of the reaction sequence shown in Fig. 1 , the number of available amino groups on HAM and I was determined by reaction with a large excess of N-acetylglycine under the conditions described for step 1. Amino acid analyses revealed that no more than 18 and 30 additional glycine residues could be incorporated into each molecule of albumin present in HAM and I respectively, indicating that 12 additional reactive amino groups had been introduced into HAM as a consequence of aminoethylation in step 1. Following thiolation in step 2, II was found to have 32.3 and 33.6 SH groups per mole of albumin as measured chemically (11) or by the incorporation of radioactivity from iodo[1-14C]acetate, respectively. As shown in Table 1 , approximately 30 molecules (17) of chain of atoms separating HAM and the succinoyl group of SPCK. Based on additional alanine residues which had been introduced into HAM as determined by amino acid analysis. Molecular weight of albumin in HAM was assumed to be 69,000, to which was added the molecular weight of the spacer arm and of SPCK. § Based on values for 50% inhibition of elastase activity in curves shown in Fig. 2 . Curve for SPCK not shown. Molecular weight of human leukocyte elastase was assumed to be 27,000 (12) . Fig. 1 go essentially to completion. The amount of peptide that can be attached to HAM appears to be limited only by the number of reactive amino groups that are present on HAM after aminoethylation in step 1.
The ability of the various HAM-inhibitor derivatives to inhibit human leukocyte elastase is shown in Fig. 2 . From the 50% inhibition point of these curves the quantity of elastase that would be completely inhibited by each of these derivatives was calculated; quantities are shown in Table 1 . Derivatives IIIi and V1 had the same inhibitory activity despite the difference in the lengths of their spacer arms, 24.3 A and 34.7 A, respectively. Derivative Is, on the other hand, with a spacer arm of only 11.7 A, was only one-third as inhibitory as IIIR and Vs. Although the extent to which the length of the spacer group could be shortened without a reduction in inhibitor activity was not determined, it is evident that a spacer arm greater than 24 A does not impart any additional inhibitory activity. When inhibitory activity is expressed on the basis of inhibitor peptide content, the activity of IIIj and V1 is only about 8% of that of the free inhibitor peptide, indicating that steric hindrance is still being manifested despite the insertion of an extended chain between HAM and the peptide. However, when one takes into account the number of inhibitor molecules incorporated per mole of HAM, approximately one mole of elastase is inhibited per mole of IIIj or Vs. This is essentially equivalent to the inhibitory effectiveness of a1-antitrypsin (12) , a protein normally present in blood but whose deficiency has been associated with the premature onset of emphysema (18) . Moreover, because HAM has been reported to undergo rapid proteolytic degradation in vivo (4), free peptide inhibitor might be released in vivo, which could result in an enhancement of the inhibitor activity of the HAM-inhibitor derivatives in the intact animal.
All of the data considered to this point were obtained with HAM having an average diameter of 15 ,.m. Also shown in Fig.  2 This size was chosen because it represents the smallest size microspheres that can be trapped in the lung capillary bed without escaping into the circulatory system. Although III' has the same spacer arm as IIIs, its content of attached inhibitor and the amount of elastase that it could inhibit per mole of albumin in HAM were significantly higher than in IIIs. These results are readily explained by the fact that the smaller spheres have a greater surface area per unit weight and thus would be expected to have a greater number of exposed functional groups available for chemical modification. Experiments in vivo with inhibitor-bound microspheres As shown in Fig. 3 , approximately 85% of the HAM-inhibitor complex was entrapped by the lungs immediately after injection. In control experiments with the underivatized microspheres about 75% of the microspheres were immediately entrapped in the lungs and their subsequent disappearance therefrom appeared to follow a simple exponential decay with a rate constant (kc) of 1.18 day-' with half-life equal to 0.58 days. The HAM-inhibitor microspheres, on the other hand, displayed a biphasic pattern of decay with an apparent initial rate constant (kl) of 0.73 day-', half-life equal to 0.95 days, followed by a much slower rate of decay (k2) of 0.04 day-', half-life equal to 17 days. In order to obtain a true initial decay constant for the derivatized microspheres, the slow decay portion of this curve was extrapolated back to zero time and subtracted from the observed fast decay component of the experimental curve. This gives a true initial rate of decay (k') of 0.55 day-' with half-life equal to 1.3 days, indicating that the derivatized microspheres were initially degraded about half Proc. Natl. Acad. Sci. USA 76 (1979) as rapidly as the underivatized controls. It may be furthermore noted from Fig. 3 that approximately 40 (20, 21) , it should be possible to demonstrate whether inhibitor-bearing microspheres can in fact prevent the development of emphysema without undue damage to the animal.
As far as the toxic effects of the inhibitor itself is concerned, it is known that chloromethyl ketones can react with other nucleophilic groups (22) (10, 24) . On the other hand, microspheres with a diameter of 1 gim, when injected intravenously, filter through the lungs and become lodged in the liver. Microspheres may also be rendered site specific through the incorporation of particles of Fe3O4, which make them responsive to an externally placed magnet (25) . The biodegradability and rate of clearance of microspheres after entrapment can likewise be controlled by their "hardness," which depends on the manner in which the microspheres have been prepared (2, 26) . It is evident that HAM are endowed with a variety of useful properties which makes them excellent candidates for drug delivery in vivo.
